Nanoviricides Inc (NNVC) Stock Price, Quote & News

Company Profile

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-...

Industry: Biotechnology

Sector: Healthcare

Phone: 203 937 6137

Website: www.nanoviricides.com

Address:

1 Controls Drive, Shelton, United States

Love1010 Oct. 3 at 6:21 PM

$NNVC funny to see this collapse again

0 · Reply

highnihilism Oct. 1 at 10:34 AM

0 · Reply

STRAYNUT Sep. 30 at 11:14 AM

$NNVC On July 22, 2025, Dr. Anil Diwan attended the Bipartisan Commission on Biodefense Meeting in Washington DC. The Bipartisan Commission on Biodefense was established in 2014 to conduct a comprehensive assessment of the state of U.S. biodefense efforts, and to issue recommendations to foster change. On July 23, 2025, Dr. Anil Diwan gave a Selected Presentation on “NV-387, a Broad-Spectrum, Oral, Prophylactic and Treatment of Viral Threats to Warfighter” at the CWMD/MCDC 2025 Annual Membership Meeting in Baltimore, MD. MCDC is the Medical CBRN (Chemical Biological Radiation and Nuclear) Defense Consortium. CWMD is the Countering Weapons of Mass Destruction Consortium (https://www.medcbrn.org). Page 37 of 107 https://www.sec.gov/Archives/edgar/data/1379006/000110465925094527/nnvc-20250630x10k.htm

0 · Reply

d_risk Sep. 29 at 8:55 PM

$NNVC - NANOVIRICIDES, INC. - 10K - Updated Risk Factors NNVC’s 10-K risk factors now detail new competitive threats for smallpox, MPox, and measles drug candidates, expanded competition for shingles, HSV, and flu drugs, heightened international market instability, increased compliance costs, penny stock risks, and potential stock dilution from new equity and large share sales. #Biopharmaceuticals #StockDilution #MarketInstability #CompetitiveThreats #InfectiousDiseases 🟢 Added 🟠 Removed https://d-risk.ai/NNVC/10-K/2025-09-29

0 · Reply

STRAYNUT Sep. 29 at 5:04 AM

$NNVC Short Interest (09/15/25) Shares Sold Short 231,929 Change from Last 13.67% Percent of Float 1.50% https://www.wsj.com/market-data/quotes/NNVC

0 · Reply

CalculatedSwing Sep. 25 at 5:19 AM

$NNVC $NNVC breaking key resistance! 👀 NanoViricides' broad-spectrum antiviral platform looking strong into year-end. Multiple programs advancing, IP portfolio expanding. Volume spike + technical setup = potential runner Antiviral space heating up again 🔥 $MRNA $BVNRY $GILD $VXRT thoughts on the sector? #Biotech #Antiviral #Breakout

0 · Reply

yl_trader Sep. 19 at 3:03 PM

$NNVC in

0 · Reply

CalculatedSwing Sep. 18 at 3:24 AM

🚀 My degen portfolio is on FIRE with these undervalued beasts under $2 (except one powerhouse)! $GLMD $1.36: Aramchol biomarkers unlocking oncology goldmines, 378% to $6.50 targets! $SVRE $1.65: ADAS VRU deals equipping millions of cars, safety tech exploding! $GFAI $1.16: AI security in Thailand + gov't renewals, $4.50 PT for 300% pop! $EU $1.59: Uranium ISR ramp to 1.5M lbs/yr on AI nuke demand, $5.25 upside! $NNVC $1.45: NV-387 antiviral crushing trials for RSV/COVID, Phase II catalysts ahead! $BIVI $1.75: Neuro therapies for Alzheimer's/Parkinson's, analysts eyeing $16+! & $CORZ $16.21: HPC pivot + CoreWeave deal smashing Q2, $22 PT in crypto/AI surge! Portfolio primed for 5-10x liftoff—loading up! #PennyStocks #Biotech #Uranium #AI $LEXX $TNXP $URG $MARA

0 · Reply

CalculatedSwing Sep. 15 at 2:53 PM

$APPS check $NNVC and $GFAI

0 · Reply

Love1010 Sep. 14 at 5:44 PM

$NNVC to all new longs: you are buying air. And it will go to zero. Enjoy.

0 · Reply

NanoViricides, Inc. Has Filed its Annual Report

Sep 11, 2025, 8:30 AM EDT - 23 days ago

RETRANSMISSION: NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025

Sep 9, 2025, 8:30 AM EDT - 25 days ago

NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025

Aug 18, 2025, 8:30 AM EDT - 6 weeks ago

A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials

Jul 30, 2025, 8:30 AM EDT - 2 months ago

Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides

Jul 23, 2025, 8:30 AM EDT - 2 months ago

NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value

Jul 21, 2025, 6:30 AM EDT - 2 months ago

Measles Now Has a Drug - NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides

Jul 16, 2025, 8:30 AM EDT - 2 months ago

WHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides

Jun 18, 2025, 6:30 AM EDT - 3 months ago

With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides' Dr. Diwan

Jun 4, 2025, 6:55 AM EDT - 4 months ago

NanoViricides Measles Drug Development Animal Study is Imminent

May 28, 2025, 6:30 AM EDT - 4 months ago

NanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025

May 22, 2025, 6:30 AM EDT - 4 months ago

The New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides' Dr. Diwan

May 14, 2025, 6:30 AM EDT - 5 months ago

Measles Cases Are Increasing Globally; MPox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the Solution

May 5, 2025, 6:30 AM EDT - 5 months ago

NanoViricides, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference, May 14th, NYC

Apr 29, 2025, 6:30 AM EDT - 5 months ago

Measles is Likely to Become Endemic - NanoViricides Is Testing a Drug to Combat It

Apr 14, 2025, 6:30 AM EDT - 6 months ago

Measles Outbreak Expands Begging for a Drug to Treat the Infection - NanoViricides Declares it is Ready to Fight the Outbreak

Mar 11, 2025, 6:30 AM EDT - 7 months ago

NanoViricides Not Affected by Tariffs and Other Policies, Has Excellent Long Term Outlook, Stock-Price Decline Misguided, Explains the Company

Mar 4, 2025, 6:30 AM EST - 7 months ago

Measles Outbreak: NV-387 Promises To Be An Effective Drug To Treat Patients; We are Ready To Work With HHS, Says NanoViricides President Dr. Anil Diwan

Feb 19, 2025, 6:30 AM EST - 8 months ago

NanoViricides, Inc. Has Filed its Quarterly Report

Feb 11, 2025, 6:30 AM EST - 8 months ago

NanoViricides Drug Can Fight Bird Flu Pandemic; H5N1 Virus Cannot Escape

Jan 29, 2025, 6:30 AM EST - 8 months ago

NanoViricides to Present at the MicroCap Conference on Wednesday, January 29, 2025

Jan 27, 2025, 6:30 AM EST - 8 months ago

NanoViricides Engages CRO for Phase II Clinical Trial

Jan 13, 2025, 6:30 AM EST - 9 months ago

NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025

Jan 8, 2025, 6:30 AM EST - 9 months ago

Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals

Dec 23, 2024, 6:30 AM EST - 10 months ago

NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape

Nov 15, 2024, 6:30 AM EST - 11 months ago

NanoViricides, Inc. Has Filed Its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID

Nov 4, 2024, 12:00 AM EST - 11 months ago

NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am

Oct 22, 2024, 6:30 AM EDT - 1 year ago

NanoViricides President Dr. Diwan to Present at the PODD Conference

Oct 15, 2024, 6:30 AM EDT - 1 year ago

NanoViricides President Dr. Diwan Interviwed in PODD Podcast; He Explains the Revolutionary Clinical Stage Broad-Spectrum Antiviral NV-387, and the Potential of the Platform to Revolutionize Fields Beyond Virology

Oct 8, 2024, 6:30 AM EDT - 1 year ago

NanoViricides to Present at the Global AMR Summit 2024 Tomorrow

Sep 30, 2024, 6:30 AM EDT - 1 year ago

NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVID

Sep 26, 2024, 6:30 AM EDT - 1 year ago

NanoViricides Executes an Agreement Encompassing All Antiviral Drug Treatments With Theracour, Including “Trojan Horse” Drugs

Aug 26, 2024, 7:30 AM EDT - 1 year ago

MPOX is Emerging as a Global Threat - NanoViricides Investigating MEURI Protocol for Using NV-387 to Treat MPOX

Aug 19, 2024, 6:30 AM EDT - 1 year ago

NanoViricides Continues Its March Towards a Phase II Clinical Trial of NV-387 - A Potentially Revolutionary First Line Antiviral Therapy for RSV, COVID, and Other Viral Infections

Aug 8, 2024, 6:30 AM EDT - 1 year ago

NanoViricides Provides an Update on Its Clinical Program and Strategy - NV-387 Could be As Revolutionary as Antibiotics

Aug 2, 2024, 7:00 AM EDT - 1 year ago

Can Nanotechnology offer Better Solutions for COVID, RSV and other Viruses?

Aug 1, 2024, 6:30 AM EDT - 1 year ago

"NanoViricides Broad Spectrum Technology Represents Potential Paradigm Shift In Viral Therapy"; "Novel Anti-Viral Could Boost a US$3 Billion Market" - Conclude Two Independent Research Reports on NanoViricides

Jul 24, 2024, 6:30 AM EDT - 1 year ago

COVID is Here to Stay and NV-387 is a Much Needed Drug Against It, Reminds NanoViricides

Jul 11, 2024, 6:30 AM EDT - 1 year ago

A Single Drug Against Multiple Respiratory Virus Infections - COVID, RSV, Influenza, Bird Flu - Planning Next Phase of Clinical Trials, Says NanoViricides

Jun 24, 2024, 6:00 AM EDT - 1 year ago

A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Could Be an Important Weapon to Fight Bird Flu H5N1, Says NanoViricides

Jun 20, 2024, 6:30 AM EDT - 1 year ago

A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Is Effective in Protecting Lungs from Damage in Lethally Infected Animal Model

Jun 11, 2024, 6:30 AM EDT - 1 year ago

Orally Administered NV-387 Results in Ideal Flat Blood Concentration Profile for Sustained Antiviral Effect

Jun 4, 2024, 6:30 AM EDT - 1 year ago

The Sustained, Slow Declining, Blood Concentration Profile of NV-387 Enables Infrequent Dosing for Strong Antiviral Effect

May 20, 2024, 6:30 AM EDT - 1 year ago

Lethally RSV Infected Animals Orally Treated with NV-387 Showed Normal Lung Histology, Indicating Potential Cure

May 15, 2024, 6:30 AM EDT - 1 year ago

NanoViricides Has Filed its Quarterly Report

May 14, 2024, 6:30 AM EDT - 1 year ago

A Novel Broad-Spectrum Antiviral with Activity Against RSV

May 10, 2024, 6:30 AM EDT - 1 year ago

NanoViricides to Participate in the 2024 EF Hutton Annual Global Conference On May 15 in New York City

May 8, 2024, 6:30 AM EDT - 1 year ago

A Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox

May 6, 2024, 6:30 AM EDT - 1 year ago

A Novel Broad-Spectrum Antiviral with Activity Against Influenza A

Apr 30, 2024, 6:30 AM EDT - 1 year ago

NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon

Love1010 Oct. 3 at 6:21 PM

$NNVC funny to see this collapse again

0 · Reply

highnihilism Oct. 1 at 10:34 AM

0 · Reply

STRAYNUT Sep. 30 at 11:14 AM

0 · Reply

d_risk Sep. 29 at 8:55 PM

0 · Reply

STRAYNUT Sep. 29 at 5:04 AM

$NNVC Short Interest (09/15/25) Shares Sold Short 231,929 Change from Last 13.67% Percent of Float 1.50% https://www.wsj.com/market-data/quotes/NNVC

0 · Reply

CalculatedSwing Sep. 25 at 5:19 AM

0 · Reply

yl_trader Sep. 19 at 3:03 PM

$NNVC in

0 · Reply

CalculatedSwing Sep. 18 at 3:24 AM

0 · Reply

CalculatedSwing Sep. 15 at 2:53 PM

$APPS check $NNVC and $GFAI

0 · Reply

Love1010 Sep. 14 at 5:44 PM

$NNVC to all new longs: you are buying air. And it will go to zero. Enjoy.

0 · Reply

Love1010 Sep. 13 at 1:13 PM

$NNVC where did all these new pumpers come from? Looks like they need to be schooled!

0 · Reply

CameoBrien Sep. 12 at 8:07 PM

$NNVC not bad

0 · Reply

UltimateTrader_22 Sep. 12 at 7:55 PM

$NNVC Green all day today. Let's close at $1.45+ #Bullish

0 · Reply

CameoBrien Sep. 12 at 7:31 PM

$NNVC nit nat on the ask all day. Let it breathe

0 · Reply

UltimateTrader_22 Sep. 12 at 7:26 PM

$NNVC Let's See Power Hour🔥Swing Opportunity

0 · Reply

Stockprofiler Sep. 12 at 7:14 PM

$NNVC Closing the gap to $2 next week! #bullish

0 · Reply

CameoBrien Sep. 12 at 7:05 PM

$NNVC eod push

0 · Reply

PrnceMichael Sep. 12 at 6:53 PM

$NNVC $1.45's going now! For the last half of the year @NNVC_Inc is trading consistently higher trending and Experts predict this could breakout at any moment. #tightchannel #lowFloat #FDA @NYSE

0 · Reply

StockWorldz Sep. 12 at 6:42 PM

$NNVC 1.45's green heading into power hour!

0 · Reply

CameoBrien Sep. 12 at 6:12 PM

$NNVC 👉

0 · Reply

PrnceMichael Sep. 12 at 5:50 PM

$NNVC NanoViricide Platform Enables *Oral Drug Delivery -Oral drug delivery of small chemicals, peptides such as the GLP-a obesity drugs which is a huge market right now. Eli Lilly $LLY , Novo Nordisk $NVO prepare to face off in the next obesity drug battleground https://cnb.cx/4nroYGD Could $NNVC be a better candidate?

0 · Reply

StockWorldz Sep. 12 at 5:27 PM

$NNVC

0 · Reply

Market Cap	24.06M
Revenue (ttm)	0.00
Net Income (ttm)	-8.29M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	155,600
Avg Vol	132,028
Day's Range	N/A - N/A
Shares Out	17.43M
Stochastic %K	18%
Beta	1.16
Analysts	Strong Sell
Price Target	$6.50